Kunming Longjin Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 100.503 million compared to CNY 131.150 million a year ago. Operating loss was CNY 3.432 million compared to operating Income of CNY 3.542 million a year ago. Net loss was CNY 1.606 million compared to net income of CNY 1.340 million a year ago. Basic loss per share from continuing operations was CNY 0.004 compared to basic earnings per share from continuing operations of CNY 0.0033 a year ago.